Trial reportJournal of clinical pharmacology2012
The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.
Trial report in Journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.European journal of clinical pharmacology · 2022Pooled it
- Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis.BMC infectious diseases · 2014Pooled it
- Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.Therapeutic drug monitoring · 2012Trial
- Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.Antimicrobial agents and chemotherapy · 2011Trial
- NAT2 rs1495741 and anti-tuberculosis drug-induced liver injury in children: genetic association and risk prediction.Frontiers in pharmacology · 2026Article
- N-acetyltransferase Gene Variants Involved in Pediatric Idiosyncratic Drug-Induced Liver Injury.Biomedicines · 2024Article
- Genetic polymorphisms of pharmacogenomic VIP variants in the Hui population from Ningxia Province of China.Functional & integrative genomics · 2023Article
- Pharmacokinetics of Antimicrobials in Children with Emphasis on Challenges Faced by Low and Middle Income Countries, a Clinical Review.Antibiotics (Basel, Switzerland) · 2022Review
- Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Pharmacogenetic testing for NAT2 genotypes in a Tanzanian population across the lifespan to guide future personalized isoniazid dosing.Tuberculosis (Edinburgh, Scotland) · 2022Article
- The Impact of Pharmacogenetics on Pharmacokinetics and Pharmacodynamics in Neonates and Infants: A Systematic Review.Pharmacogenomics and personalized medicine · 2022Review
- Clinical relevance of the lnc-HNF1B-3:1 genetic polymorphisms in Western Chinese tuberculosis patients.Journal of clinical laboratory analysis · 2020Article
- Precision therapeutics in the NICU: why are we missing the mark?Journal of perinatology : official journal of the California Perinatal Association · 2018Article
- Effect of Genetic Variation ofAntimicrobial agents and chemotherapy · 2018Article
- Neonatal drug therapy: The first frontier of therapeutics for children.Clinical pharmacology and therapeutics · 2015Review
- Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research.The Journal of infectious diseases · 2015Review
- Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.The Journal of antimicrobial chemotherapy · 2014Article
- Pharmacokinetics of isoniazid in low-birth-weight and premature infants.Antimicrobial agents and chemotherapy · 2014Article
- Clinical pharmacology in neonates: small size, huge variability.Neonatology · 2014Review
- Neonatal clinical pharmacology.Paediatric anaesthesia · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection. Plasma concentration-time measurements of isoniazid from 151 infants (starting at 3-4 months of age) receiving isoniazid 10 to 20 mg/kg/d orally during the course of the 24-month study were incorporated in a population analysis along with NAT2 genotype, body weight, age, and sex. The results showed a different NAT2 enzyme maturation profile for each of the 3 acetylation groups, with the 70-kg body weight-normalized typical apparent clearance for the fast and intermediate acetylators increasing from 14.25 L/h and 10.88 L/h at 3 months of age to 22.84 L/h and 15.58 L/h at 24 months of age, respectively, with no significant change in the apparent clearance of the slow group during this period. A hypothesis is proposed to explain the genotype-dependent enzyme maturation processes for the NAT2 enzyme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.